StreetInsider.com News Articles

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT

King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL^® siRNA platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas. The presentation will be followed by a live Q&A session. This release corrects the day of the week that the

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 12:30:00 -0400

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 07:00:00 -0400

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT

"We look forward to engaging with investors at the Renmark Financial Virtual

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Wed, 22 Jul 2026 07:00:00 -0400

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT

"We look forward to engaging with investors at the Renmark Financial Virtual

Form 8-K Phio Pharmaceuticals For: Jul 21

Tue, 21 Jul 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260721/26792085.html

Form 8-K Phio Pharmaceuticals For: Jul 21

Tue, 21 Jul 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260721/26792085.html

Phio Pharmaceuticals adds dermatologist to its board of directors

Tue, 21 Jul 2026 07:01:08 -0400

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has appointed R. Todd Plott, M.D., to its board of directors, the clinical-stage biopharmaceutical company announced.

Dr. Plott is a board-certified dermatologist with more than 30 years of experience in dermatologic care. He has overseen hundreds of clinical trials and served on the FDA Dermatologic and Ophthalmic Drug Advisory Committee from 2016 to 2021. He currently operates a private practice focused on complex skin diseases, acne, and skin cancer.

Robert Bitterman, CEO and Chairman of the Board, said Dr. Plott's dermatology practice experience and clinical development expertise provide "a valuable resource to Phio as we advance PH-762

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Tue, 21 Jul 2026 07:00:00 -0400

Brings extensive experience in patient care, dermatologic research and commercialization

King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals.

Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation. He has played a significant role in advancing

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Tue, 21 Jul 2026 07:00:00 -0400

Brings extensive experience in patient care, dermatologic research and commercialization

Phio Pharmaceuticals receives patent approvals in U.S., Canada, and Japan

Wed, 15 Jul 2026 07:02:54 -0400

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced it has received three notices of allowance and one grant decision for patents covering its INTASYL gene silencing technology in the United States, Canada, and Japan.

According to the company's press release, the new actions bring its total issued patent portfolio to 54 patents. The portfolio covers INTASYL chemistry, specific gene targets, immuno-oncology compounds, and therapeutic indications across multiple countries.

"Strong patent protection is an important component of our strategy to advance innovative immuno-oncology therapies and maximize the long-term value of our INTASYL siRNA platform," said Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals.

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Wed, 15 Jul 2026 07:00:00 -0400

Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds

King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the protection of its proprietary innovations across key international markets. The company has received multiple favorable patent actions encompassing three notices of allowance and one grant decision to further strengthen Phio's global intellectual property portfolio in the United States, Canada, and Japan, respectively. This reinforces the

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Wed, 15 Jul 2026 07:00:00 -0400

Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds

Form 4 Phio Pharmaceuticals For: Jun 26 Filed by: Bitterman Robert J

Mon, 29 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260629/26706309.html

Form 4 Phio Pharmaceuticals For: Jun 26 Filed by: Bitterman Robert J

Mon, 29 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260629/26706309.html

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Fri, 26 Jun 2026 08:35:00 -0400

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24^th & 25^th Life Sciences Virtual Investor Forum are now available for on-demand viewing.

REGISTER AND VIEW PRESENTATIONS HERE

Select companies are accepting 1x1 management meeting requests through June 19^th. Please Schedule 1x1 Meetings here.